FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4375852232> ?p ?o ?g. }

• W4375852232 endingPage "e374" @default.
• W4375852232 startingPage "e363" @default.
• W4375852232 abstract "Drugs taken during pregnancy can affect maternal and child health outcomes, but few studies have compared the safety and virological efficacy of different antiretroviral therapy (ART) regimens. We report the primary safety outcomes from enrolment up to 50 weeks post partum and a secondary virological efficacy outcome at 50 weeks post partum of three commonly used ART regimens for HIV-1.In this multicentre, open-label, randomised, controlled, phase 3 trial, we enrolled pregnant women aged 18 years or older with confirmed HIV-1 infection at 14-28 weeks of gestation. Women were enrolled at 22 clinical research sites in nine countries (Botswana, Brazil, India, South Africa, Tanzania, Thailand, Uganda, the USA, and Zimbabwe). Participants were randomly assigned (1:1:1) to one of three oral regimens: dolutegravir, emtricitabine, and tenofovir alafenamide; dolutegravir, emtricitabine, and tenofovir disoproxil fumarate; or efavirenz, emtricitabine, and tenofovir disoproxil fumarate. Up to 14 days of antepartum ART before enrolment was permitted. Women with known multiple gestation, fetal anomalies, acute significant illness, transaminases more than 2·5 times the upper limit of normal, or estimated creatinine clearance of less than 60 mL/min were excluded. Primary safety analyses were pairwise comparisons between ART regimens of the proportion of maternal and infant adverse events of grade 3 or higher up to 50 weeks post partum. Secondary efficacy analyses at 50 weeks post partum included a comparison of the proportion of women with plasma HIV-1 RNA of less than 200 copies per mL in the combined dolutegravir-containing groups versus the efavirenz-containing group. Analyses were done in the intention-to-treat population, which included all randomly assigned participants with available data. This trial was registered with ClinicalTrials.gov, NCT03048422.Between Jan 19, 2018, and Feb 8, 2019, we randomly assigned 643 pregnant women to the dolutegravir, emtricitabine, and tenofovir alafenamide group (n=217), the dolutegravir, emtricitabine, and tenofovir disoproxil fumarate group (n=215), and the efavirenz, emtricitabine, and tenofovir disoproxil fumarate group (n=211). At enrolment, median gestational age was 21·9 weeks (IQR 18·3-25·3), median CD4 count was 466 cells per μL (308-624), and median HIV-1 RNA was 903 copies per mL (152-5183). 607 (94%) women and 566 (92%) of 617 liveborn infants completed the study. Up to the week 50 post-partum visit, the estimated probability of experiencing an adverse event of grade 3 or higher was 25% in the dolutegravir, emtricitabine, and tenofovir alafenamide group; 31% in the dolutegravir, emtricitabine, and tenofovir disoproxil fumarate group; and 28% in the efavirenz, emtricitabine, and tenofovir disoproxil fumarate group (no significant difference between groups). Among infants, the estimated probability of experiencing at least one adverse event of grade 3 or higher by postnatal week 50 was 28% overall, with small and non-statistically significant differences between groups. By postnatal week 50, 14 infants whose mothers were in the efavirenz-containing group (7%) died, compared with six in the combined dolutegravir groups (1%). 573 (89%) women had HIV-1 RNA data available at 50 weeks post partum: 366 (96%) in the dolutegravir-containing groups and 186 (96%) in the efavirenz-containing group had HIV-1 RNA less than 200 copies per mL, with no significant difference between groups.Safety and efficacy data during pregnancy and up to 50 weeks post partum support the current recommendation of dolutegravir-based ART (particularly in combination with emtricitabine and tenofovir alafenamide) rather than efavirenz, emtricitabine, and tenofovir disoproxil fumarate, when started in pregnancy.National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health." @default.
• W4375852232 created "2023-05-10" @default.
• W4375852232 creator A5000473129 @default.
• W4375852232 creator A5000990498 @default.
• W4375852232 creator A5002231578 @default.
• W4375852232 creator A5002870956 @default.
• W4375852232 creator A5003998272 @default.
• W4375852232 creator A5004561498 @default.
• W4375852232 creator A5008035681 @default.
• W4375852232 creator A5008686211 @default.
• W4375852232 creator A5009887015 @default.
• W4375852232 creator A5010254245 @default.
• W4375852232 creator A5012259435 @default.
• W4375852232 creator A5012262637 @default.
• W4375852232 creator A5012893141 @default.
• W4375852232 creator A5015684343 @default.
• W4375852232 creator A5016244756 @default.
• W4375852232 creator A5016249980 @default.
• W4375852232 creator A5016918314 @default.
• W4375852232 creator A5018774398 @default.
• W4375852232 creator A5019594570 @default.
• W4375852232 creator A5019896304 @default.
• W4375852232 creator A5020405624 @default.
• W4375852232 creator A5022590358 @default.
• W4375852232 creator A5023110042 @default.
• W4375852232 creator A5024408755 @default.
• W4375852232 creator A5025772367 @default.
• W4375852232 creator A5026494923 @default.
• W4375852232 creator A5027651822 @default.
• W4375852232 creator A5029038051 @default.
• W4375852232 creator A5029916608 @default.
• W4375852232 creator A5030501259 @default.
• W4375852232 creator A5030744787 @default.
• W4375852232 creator A5031053580 @default.
• W4375852232 creator A5031364451 @default.
• W4375852232 creator A5031386421 @default.
• W4375852232 creator A5032758750 @default.
• W4375852232 creator A5032863083 @default.
• W4375852232 creator A5033299453 @default.
• W4375852232 creator A5035865634 @default.
• W4375852232 creator A5036519336 @default.
• W4375852232 creator A5037231987 @default.
• W4375852232 creator A5037335963 @default.
• W4375852232 creator A5038561962 @default.
• W4375852232 creator A5039508578 @default.
• W4375852232 creator A5039731482 @default.
• W4375852232 creator A5040538996 @default.
• W4375852232 creator A5040635687 @default.
• W4375852232 creator A5042729464 @default.
• W4375852232 creator A5043966092 @default.
• W4375852232 creator A5044413376 @default.
• W4375852232 creator A5044694494 @default.
• W4375852232 creator A5045831425 @default.
• W4375852232 creator A5046351008 @default.
• W4375852232 creator A5046971748 @default.
• W4375852232 creator A5047491348 @default.
• W4375852232 creator A5048362513 @default.
• W4375852232 creator A5048941667 @default.
• W4375852232 creator A5049054494 @default.
• W4375852232 creator A5049122372 @default.
• W4375852232 creator A5049574497 @default.
• W4375852232 creator A5049620208 @default.
• W4375852232 creator A5049983194 @default.
• W4375852232 creator A5051354157 @default.
• W4375852232 creator A5055824963 @default.
• W4375852232 creator A5056461645 @default.
• W4375852232 creator A5056780586 @default.
• W4375852232 creator A5058620608 @default.
• W4375852232 creator A5058810040 @default.
• W4375852232 creator A5060050168 @default.
• W4375852232 creator A5061291195 @default.
• W4375852232 creator A5061419637 @default.
• W4375852232 creator A5061678795 @default.
• W4375852232 creator A5061800035 @default.
• W4375852232 creator A5062330340 @default.
• W4375852232 creator A5063598622 @default.
• W4375852232 creator A5064744595 @default.
• W4375852232 creator A5064787976 @default.
• W4375852232 creator A5066129926 @default.
• W4375852232 creator A5069668489 @default.
• W4375852232 creator A5070719160 @default.
• W4375852232 creator A5071318705 @default.
• W4375852232 creator A5071429623 @default.
• W4375852232 creator A5071515546 @default.
• W4375852232 creator A5075268427 @default.
• W4375852232 creator A5077436590 @default.
• W4375852232 creator A5077829337 @default.
• W4375852232 creator A5078636473 @default.
• W4375852232 creator A5080879626 @default.
• W4375852232 creator A5081233385 @default.
• W4375852232 creator A5081328251 @default.
• W4375852232 creator A5081854376 @default.
• W4375852232 creator A5082157757 @default.
• W4375852232 creator A5084353681 @default.
• W4375852232 creator A5084460636 @default.
• W4375852232 creator A5084890323 @default.
• W4375852232 creator A5085000841 @default.
• W4375852232 creator A5085401913 @default.

• next